Core Viewpoint - The Shenzhen Stock Exchange has issued regulatory measures against Minsheng Securities and other involved parties due to violations during the IPO process of Dijia Pharmaceutical Group Co., Ltd, highlighting issues related to independence, internal controls, and financial disclosures [1][2][8]. Group 1: Regulatory Actions - The Shenzhen Stock Exchange decided to take written warning measures against Minsheng Securities for failing to adequately address independence issues of the issuer [8][20]. - Minsheng Securities' representatives, Bao Jingjing and He Runyong, received public criticism for their inadequate scrutiny of the issuer's independence and internal control issues [22][28]. - The audit firm Tianjian CPA and its signatory accountants, Fei Fanghua and Peng Xianglian, were also criticized for not properly addressing internal control deficiencies [30][36]. Group 2: Issuer's Independence Issues - Dijia Pharmaceutical was found to have independence flaws, as it prioritized purchasing from suppliers controlled by its actual controller, leading to conflicts of interest [3][12][41]. - Employees from the controlling shareholder, Dishan Group, were involved in procurement processes, raising concerns about the independence of the issuer's operations [3][12][41]. - The issuer failed to disclose these independence issues in accordance with the relevant disclosure guidelines [12][41]. Group 3: Internal Control Deficiencies - The issuer's internal controls regarding procurement, sales, and inventory management were found to be inadequate, with missing documentation and improper handling of transactions [4][6][26]. - Significant payments made by Dishan Group and its subsidiaries were not properly verified, leading to questions about the legitimacy of these transactions [4][10][32]. - The issuer's handling of returns related to unsold products was also criticized, as the accounting treatment did not align with actual contractual agreements [19][40]. Group 4: Financial Disclosure Issues - The issuer's financial disclosures were deemed inaccurate, particularly regarding the treatment of returns, which should have impacted the 2020 revenue figures instead of 2019 [19][40]. - The audit and legal representatives failed to provide accurate assessments of the issuer's financial practices, leading to further regulatory scrutiny [30][42][46].

文/末日机甲 4月30日晚上，深交所公布3份书面警示监管函、3份通报批评处分的决定。2023 年 6 月 16 日，深交所受理了迪嘉药业集团股份有限公司创业板IPO的申请。该IPO 项目的保荐机构、法律服务机构、审计服务机构分别为民生证券、上海泽昌律师事务所、天健会计师事务所。迪嘉药业注册地山东威海，其创业板IPO于2024年6月 12日被终止审核。 | 。 关于对天健会计师事务所 (特殊普通合伙) 的监管函 | 2025-04-30 | | --- | --- | | · 关于对上海泽昌律师事务所的监管函 | 2025-04-30 | | · 关于对民生证券股份有限公司的监管函 | 2025-04-30 | | · 关于对迪嘉药业集团股份有限公司及相关当事人给予通报批评处分的决定 | 2025-04-30 | | 。 关于对签字律师刘波、石百新给予通报批评处分的决定 | 2025-04-30 | | 。 关于对保荐代表人包静静、何润勇给予通报批评处分的决定 | 2025-04-30 | 经深交所现场督导发现： 在本次发行上市申请过程中，发行人及相关当事人（实控人王德军董事长、实控人王琳嘉董事、总经理王丹琦、 ...